JP2019511547A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511547A5
JP2019511547A5 JP2018554061A JP2018554061A JP2019511547A5 JP 2019511547 A5 JP2019511547 A5 JP 2019511547A5 JP 2018554061 A JP2018554061 A JP 2018554061A JP 2018554061 A JP2018554061 A JP 2018554061A JP 2019511547 A5 JP2019511547 A5 JP 2019511547A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
methyl
composition according
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018554061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511547A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/058552 external-priority patent/WO2017178428A1/en
Publication of JP2019511547A publication Critical patent/JP2019511547A/ja
Publication of JP2019511547A5 publication Critical patent/JP2019511547A5/ja
Pending legal-status Critical Current

Links

JP2018554061A 2016-04-13 2017-04-10 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ Pending JP2019511547A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321983P 2016-04-13 2016-04-13
US62/321,983 2016-04-13
PCT/EP2017/058552 WO2017178428A1 (en) 2016-04-13 2017-04-10 Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer

Publications (2)

Publication Number Publication Date
JP2019511547A JP2019511547A (ja) 2019-04-25
JP2019511547A5 true JP2019511547A5 (https=) 2020-05-21

Family

ID=58503644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554061A Pending JP2019511547A (ja) 2016-04-13 2017-04-10 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ

Country Status (4)

Country Link
US (1) US20190160054A1 (https=)
EP (1) EP3442534A1 (https=)
JP (1) JP2019511547A (https=)
WO (1) WO2017178428A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202532079A (zh) * 2024-02-05 2025-08-16 瑩碩生技醫藥股份有限公司 醫藥組成物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
HRP20230523T1 (hr) * 2013-09-06 2023-08-04 Taiho Pharmaceutical Co., Ltd. Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta

Similar Documents

Publication Publication Date Title
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
JP2019521087A5 (https=)
RU2006121337A (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
JP2017516775A5 (https=)
TR201807411T4 (tr) DNA-PK inhibitörleri.
JP2019506403A5 (https=)
ES2717898T3 (es) Efecto potenciador para agentes antitumorales
JP2019510832A5 (https=)
JP2017512791A5 (https=)
JP2019532051A5 (https=)
JP2016523974A5 (https=)
RU2014109776A (ru) Лечение антителами против vegf
JP2017504611A5 (https=)
JP2021501145A5 (https=)
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
RU2008120848A (ru) Производные 4-(3-аминопиразол)пиримида для применения в качестве ингибиторов тирозинкиназы для лечения злокачественного новообразования
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
JP2006523216A5 (https=)
JP2018505193A5 (https=)
RU2016129953A (ru) Фармацевтические комбинации
JO2958B1 (en) Salts 3,2-dihydroimidazo [2.1 C-] quinazolin substituted
JP2016525097A5 (https=)
JP2018090566A5 (https=)
JP2012509263A5 (https=)
JP2017501983A5 (https=)